The OncFive: Top Oncology Articles for the Week of 4/6

FDA OKs First-line Nivolumab + Ipilimumab in Advanced HCC

Approval for the combination therapy is based on improved survival and response rates from CHECKMATE-9DW. Medscape Medical News

The OncFive: Top Oncology Articles for the Week of 4/6

Nivolumab/ipilimumab is approved for dMMR/MSI-H mCRC and unresectable or metastatic HCC, larotrectinib wins full approval in NTRK+ solid tumors, and more.

Bristol Myers' immunotherapy combo nets approvals in colorectal and liver cancer

Bristol Myers Squibb’s combined immunotherapies Opdivo and Yervoy won approval this week as a first-line treatment for metastatic liver cancer and certain forms of colorectal cancer. Both approvals make the combination available as an earlier ...

FDA Approves Nivolumab With Ipilimumab for First-Line Treatment of Adult Patients With HCC

Patients with unresectable or metastatic hepatocellular carcinoma (HCC) receiving this regimen had favorable median overall survival (23.7 months) compared with standard of care (20.6 months).

FDA Approves Nivolumab/Ipilimumab for Metastatic or Unresectable HCC

The FDA has granted approval to nivolumab plus ipilimumab for use in unresectable or metastatic hepatocellular carcinoma.

FDA Approves Opdivo Plus Yervoy for Advanced HCC

The FDA has approved Opdivo with Yervoy for the first-line treatment of adults with unresectable or metastatic hepatocellular carcinoma.